RT Journal Article
SR Electronic
T1 Association of trajectories of depressive symptoms with vascular risk, cognitive function and adverse brain outcomes: The Whitehall II MRI sub-study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20106963
DO 10.1101/2020.05.20.20106963
A1 Demnitz, N
A1 Anatürk, M
A1 Allan, CL
A1 Filippini, N
A1 Griffanti, L
A1 Mackay, CE
A1 Mahmood, A
A1 Sexton, CE
A1 Suri, S
A1 Topiwala, AG
A1 Zsoldos, E
A1 Kivimäki, M
A1 Singh-Manoux, A
A1 Ebmeier, KP
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.20.20106963.abstract
AB Background Trajectories of depressive symptoms over the lifespan vary between people, but it is unclear whether these differences exhibit distinct characteristics in brain structure and function.Methods In order to compare indices of white matter microstructure and cognitive characteristics of groups with different trajectories of depressive symptoms, we examined 774 participants of the Whitehall II Imaging Sub-study, who had completed the depressive subscale of the General Health Questionnaire up to nine times over 25 years. Twenty-seven years after the first examination, participants underwent magnetic resonance imaging to characterize white matter hyperintensities (WMH) and microstructure and completed neuropsychological tests to assess cognition. Twenty-nine years after the first examination, participants completed a further cognitive screening test.Results Using K-means cluster modelling, we identified five trajectory groups of depressive symptoms: consistently low scorers (“low”; n=505, 62.5%), a subgroup with an early peak in depression scores (“early”; n=123, 15.9%), intermediate scorers (“middle”; n=89, 11.5%), a late symptom subgroup with an increase in symptoms towards the end of the follow-up period (“late”; n=29, 3.7%), and consistently high scorers (“high”; n=28, 3.6%). The late, but not the consistently high scorers, showed higher mean diffusivity, larger volumes of WMH and impaired executive function. In addition, the late subgroup had higher Framingham Stroke Risk scores throughout the follow-up period, indicating a higher load of vascular risk factors.Conclusions Our findings suggest that tracking depressive symptoms in the community over time may be a useful tool to identify phenotypes that show different etiologies and cognitive and brain outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the MRC grants “Predicting MRI abnormalities with longitudinal data of the Whitehall II Sub-study” (PI KPE), ClinicalTrials.gov Identifier: NCT03335696, and “Adult Determinants of Late Life Depression, Cognitive Decline and Physical Functioning - The Whitehall II Ageing Study” (PI: MK). This research was supported by the NIHR Oxford Health Biomedical Research Centre. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). MK is supported by the MRC (MR/S011676/1, MR/R024227), NIH (R01AG056477, RF1AG062553), and the Academy of Finland. ASM is supported by grants from the National Institute on Aging, NIH (R01AG056477, RF1AG062553). CES is now a full-time employee of the Alzheimer's Association. Work on the Whitehall Imaging Sub-study was funded by the UK Medical Research Council (G1001354), and the HDH Wills 1965 Charitable Trust (1117747). While working on this research study, EZs and SS were funded by the EU Horizon 2020 grant (732592).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study follows Medical Research Council data sharing policies (https://mrc.ukri.org/research/policies-and-guidance-for-researchers/data-sharing/). In accordance with these guidelines, data from the Whitehall II Imaging Substudy is accessible via the Dementias Platform UK (https://portal.dementiasplatform.uk/), through formal request to the data sharing committee (https://www.ucl.ac.uk/iehc/research/epidemiology-public-health/research/whitehallII/data-sharing).